[go: up one dir, main page]

PH12013500991A1 - 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS - Google Patents

4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS

Info

Publication number
PH12013500991A1
PH12013500991A1 PH1/2013/500991A PH12013500991A PH12013500991A1 PH 12013500991 A1 PH12013500991 A1 PH 12013500991A1 PH 12013500991 A PH12013500991 A PH 12013500991A PH 12013500991 A1 PH12013500991 A1 PH 12013500991A1
Authority
PH
Philippines
Prior art keywords
phenylsulfanylmethyl
mglur
bicyclo
antagonists
substituted
Prior art date
Application number
PH1/2013/500991A
Inventor
Renhua Li
Charles Howard Mitch
Stephon Cornell Smith
Tatiana Natali Vetman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45099188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500991(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12013500991A1 publication Critical patent/PH12013500991A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A mGlu2/3 receptor antagonist of the formula (I):, its uses, and methods for its preparation are described.
PH1/2013/500991A 2010-11-18 2011-11-15 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS PH12013500991A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41512110P 2010-11-18 2010-11-18
PCT/US2011/060730 WO2012068067A1 (en) 2010-11-18 2011-11-15 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists

Publications (1)

Publication Number Publication Date
PH12013500991A1 true PH12013500991A1 (en) 2015-02-11

Family

ID=45099188

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500991A PH12013500991A1 (en) 2010-11-18 2011-11-15 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS

Country Status (37)

Country Link
US (1) US8629169B2 (en)
EP (1) EP2640697B1 (en)
JP (1) JP5877847B2 (en)
KR (2) KR20130101094A (en)
CN (1) CN103228625B (en)
AR (1) AR083845A1 (en)
AU (1) AU2011329076B2 (en)
BR (1) BR112013012118A2 (en)
CA (1) CA2818116C (en)
CL (1) CL2013001345A1 (en)
CO (1) CO6761385A2 (en)
CR (1) CR20130178A (en)
DK (1) DK2640697T3 (en)
DO (1) DOP2013000099A (en)
EA (1) EA021724B1 (en)
EC (1) ECSP13012629A (en)
ES (1) ES2650139T3 (en)
GT (1) GT201300126A (en)
HR (1) HRP20171649T1 (en)
HU (1) HUE037457T2 (en)
IL (1) IL225843A (en)
LT (1) LT2640697T (en)
MA (1) MA34663B1 (en)
MX (1) MX339973B (en)
NO (1) NO2640697T3 (en)
NZ (1) NZ609816A (en)
PE (1) PE20140997A1 (en)
PH (1) PH12013500991A1 (en)
PL (1) PL2640697T3 (en)
PT (1) PT2640697T (en)
RS (1) RS56535B1 (en)
SG (1) SG189959A1 (en)
SI (1) SI2640697T1 (en)
TW (1) TWI520935B (en)
UA (1) UA110039C2 (en)
WO (1) WO2012068067A1 (en)
ZA (1) ZA201302918B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079343A1 (en) * 2009-12-21 2012-01-18 Lilly Co Eli ACID COMPOUND 2-AMINO-4- (4H-1,2,4-TRIAZOL-3-ILSULFANIL) BICYCLE [3.1.0] HEXANO-2,6-DICARBOXILICO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT USEFUL TO TREAT A PSYCHIATRIC DISORDER
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
AU2017254266B2 (en) 2016-04-18 2021-03-11 Taisho Pharmaceutical Co., Ltd. Prodrug of amino acid derivative
EP3570832A4 (en) 2017-01-17 2020-06-10 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0669928B2 (en) 1987-10-06 1994-09-07 宇部興産株式会社 Photopolymerizable dental material
JP2589812B2 (en) 1989-07-05 1997-03-12 松下電器産業株式会社 Steam iron
JP2000500752A (en) 1995-11-16 2000-01-25 イーライ・リリー・アンド・カンパニー Excitatory amino acid receptor antagonist
ZA969485B (en) 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
DE69919142T2 (en) * 1998-03-17 2005-01-20 Pfizer Products Inc., Groton BICYCLO [2.2.1] HEPTANESE AND RELATED COMPOUNDS
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
CH694053A5 (en) 1998-09-03 2004-06-30 Hoffmann La Roche Ver method for the production of 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives.
EP1370519A1 (en) * 2001-02-22 2003-12-17 Eli Lilly And Company Synthetic excitatory amino acids
RU2315622C2 (en) 2001-12-27 2008-01-27 Тайсо Фармасьютикал Ко.,Лтд. Derivatives of 6-fluorobicyclo[3.1.0]hexane
HRP20090058A2 (en) 2002-06-11 2009-04-30 Eli Lilly And Company Precursor Forms of Drugs for Amino Acids with Incentive Activity
JP2007063129A (en) 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd 2-Amino-3-alkoxybicyclo [3.1.0] hexane derivatives
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
ATE487690T1 (en) * 2003-06-26 2010-11-15 Taisho Pharmaceutical Co Ltd 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBONIC ACID ESTER DERIVATIVE
AR079343A1 (en) * 2009-12-21 2012-01-18 Lilly Co Eli ACID COMPOUND 2-AMINO-4- (4H-1,2,4-TRIAZOL-3-ILSULFANIL) BICYCLE [3.1.0] HEXANO-2,6-DICARBOXILICO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT USEFUL TO TREAT A PSYCHIATRIC DISORDER

Also Published As

Publication number Publication date
CA2818116C (en) 2016-04-05
EA021724B1 (en) 2015-08-31
HUE037457T2 (en) 2018-08-28
AU2011329076B2 (en) 2015-03-12
EP2640697A1 (en) 2013-09-25
LT2640697T (en) 2018-01-10
JP2014505664A (en) 2014-03-06
CR20130178A (en) 2013-07-09
MX339973B (en) 2016-06-20
UA110039C2 (en) 2015-11-10
TWI520935B (en) 2016-02-11
CA2818116A1 (en) 2012-05-24
US20120129902A1 (en) 2012-05-24
AR083845A1 (en) 2013-03-27
RS56535B1 (en) 2018-02-28
ZA201302918B (en) 2014-10-29
MX2013005622A (en) 2013-07-05
ES2650139T3 (en) 2018-01-17
JP5877847B2 (en) 2016-03-08
DOP2013000099A (en) 2013-08-15
IL225843A (en) 2015-05-31
PL2640697T3 (en) 2018-02-28
KR20130101094A (en) 2013-09-12
WO2012068067A1 (en) 2012-05-24
AU2011329076A1 (en) 2013-05-02
GT201300126A (en) 2014-02-27
NZ609816A (en) 2014-12-24
MA34663B1 (en) 2013-11-02
KR20150140876A (en) 2015-12-16
NO2640697T3 (en) 2018-02-17
SG189959A1 (en) 2013-06-28
PE20140997A1 (en) 2014-08-25
CN103228625B (en) 2014-12-03
BR112013012118A2 (en) 2016-09-27
CL2013001345A1 (en) 2013-11-15
SI2640697T1 (en) 2017-11-30
IL225843A0 (en) 2013-06-27
ECSP13012629A (en) 2013-07-31
HRP20171649T1 (en) 2017-12-15
DK2640697T3 (en) 2017-10-23
TW201307271A (en) 2013-02-16
CN103228625A (en) 2013-07-31
US8629169B2 (en) 2014-01-14
EP2640697B1 (en) 2017-09-20
CO6761385A2 (en) 2013-09-30
EA201390498A1 (en) 2013-07-30
PT2640697T (en) 2017-12-11

Similar Documents

Publication Publication Date Title
GB201017345D0 (en) Receptor antagonists
MY181898A (en) Heterocyclic compounds and uses thereof
GEP201706745B (en) Forms of rifaximin and usage thereof
MX2012007507A (en) Heteroaryl compounds and uses thereof.
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
MY160665A (en) Spiropiperidine compounds as orl-1 receptor antagonists
AP2012006630A0 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin B1 receptor
PH12013500991A1 (en) 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS
MX2013005623A (en) 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS.
PH12013500210A1 (en) Highly crystalline valsartan
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
WO2012139074A3 (en) Migrastatins and uses thereof
TN2013000209A1 (en) 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists
IL225763A0 (en) Preparation of bicyclo[2.2.2]octan-2-one compounds
HK40120913A (en) 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
WO2013067105A3 (en) Nicotinic receptor non-competitive modulators
MX2012013075A (en) Novel methods for the preparation of p2x7r antagonists.
UA54879U (en) Use of antagonist of interleukin-1 receptor as antioxidant agent
WO2012094437A3 (en) Nicotinic receptor non-competitive antagonists
UA108500C2 (en) Noncompetitive antagonists of nicotinic receptors
UA51902U (en) use of interleukin-1 receptor antagonists (aryl-1) as frigoprotective agent
UA40770U (en) use of interleukine-1 receptor antagonist as cardioprotective agent
PL392583A1 (en) Process for the preparation of 2,3-di(metoxycarbonyl)-5-norbornene
UA74358U (en) Phytotea composition
UA56041U (en) 1,3-dimethyl-7-n-methylbenzene-8-n-hydrazinoxanthine exhibiting diuretic action